Testimony, Comments, & Letters

;

Senate testimony on FY26 appropriations for HIV and hepatitis

Jun 13, 2025

As a nation, we are able to advance efforts to end the HIV and viral hepatitis epidemics. We possess proven prevention tools, including pre-exposure prophylaxis medication (PrEP), and effective treatments. We urge you to continue your historically strong commitment and leverage this pivotal moment to support the nation’s public health by comprehensively addressing these chronic diseases. Increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis and allow us to continue to hold the promise of ending these epidemics.

read more

Request for Nevada governor to veto AB259 establishing maximum fair price limits for prescription drugs

Jun 11, 2025

While we support efforts to make prescription drugs more affordable, we respectfully urge you to veto Assembly Bill 259 because it would impose harmful and untested price controls without guaranteeing savings for patients. AB 259 would prohibit any entity in Nevada from purchasing or seeking reimbursement for a prescription drug at a price higher than the flawed and untested federally determined Maximum Fair Price (MFP), as established under the Inflation Reduction Act (IRA). This effectively creates a blanket price cap for all state regulated health plans, based on prices negotiated exclusively for Medicare beneficiaries.

read more

39 groups urge USPSTF to update its 2023 HIV PrEP recommendation

May 30, 2025

We urge the U.S. Preventive Services Task Force (USPSTF) to expeditiously update its 2023 HIV Pre-Exposure Prophylaxis (PrEP) recommendation to incorporate important new evidence, including clinical trial data on lenacapavir, a new twice-yearly PrEP formulation, and new findings on PrEP’s effectiveness in women and other key populations.

read more

Opposition to Massachusetts S.875 to Create a Prescription Drug Accountability Board

May 29, 2025

The HIV+Hepatitis Policy Institute remains committed to advancing policies that ensure access to affordable medications while fostering the development needed to fight HIV and hepatitis. We urge you to oppose S.875 and recommend exploring alternative approaches that directly address affordability without risking access or undermining medical advancements.

read more

Support for Wisconsin SB203 to ban copay accumulators

May 27, 2025

The HIV+Hepatitis Policy Institute, a leading organization advocating for equitable and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic health conditions, strongly supports the provision in Senate Bill 203 that ensures third-party copay assistance counts toward patients’ deductibles and out-of-pocket maximums.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest